Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesPayablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CervoMed (CRVO) Accounts Payables (2022 - 2025)

CervoMed's Accounts Payables history spans 9 years, with the latest figure at $1.3 million for Q3 2025.

  • For Q3 2025, Accounts Payables rose 24.65% year-over-year to $1.3 million; the TTM value through Sep 2025 reached $1.3 million, up 24.65%, while the annual FY2024 figure was $1.5 million, 128.15% up from the prior year.
  • Accounts Payables for Q3 2025 was $1.3 million at CervoMed, down from $1.8 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $1.9 million in Q1 2025 and bottomed at $97302.0 in Q4 2022.
  • The 4-year median for Accounts Payables is $846032.0 (2022), against an average of $981262.7.
  • The largest YoY upside for Accounts Payables was 580.84% in 2023 against a maximum downside of 33.89% in 2023.
  • A 4-year view of Accounts Payables shows it stood at $97302.0 in 2022, then surged by 580.84% to $662471.0 in 2023, then soared by 128.15% to $1.5 million in 2024, then fell by 10.73% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for CRVO's Accounts Payables are $1.3 million (Q3 2025), $1.8 million (Q2 2025), and $1.9 million (Q1 2025).